Mutations in the MADS and MEF2 domains represented 79% of MEF2B mutations in DLBCL [143–146], 75% of MEF2B mutations in FL [143] and 93% of MEF2B mutations in MCL [147, 148]. The gene discussed is MEF2B; the disease is diffuse large B-cell lymphoma.